Article Sidebar

PDF
Date Published: 12/06/2023
Online Published: 12/06/2023
Abstract Views: 87
Views PDF: 156
Issue
No. 28 (2020)
Section
Article
How to Cite
Truong, T. A. T., Diep, G. H., Vuong, T. K. H., Le , V. T., Vo , V. Q., Nguyen , A. N., Le , T. C. T., & Nguyen , T. (2023). DRUG-DRUG INTERACTIONS IN THE PRESCRIBING FOR OUTPATIENTS WITH CORONARY ARTERY DISEASES IN CAN THO. Cantho Journal of Medicine and Pharmacy, 28, 143-148. https://tapchi.ctump.edu.vn/index.php/ctump/article/view/1641

DRUG-DRUG INTERACTIONS IN THE PRESCRIBING FOR OUTPATIENTS WITH CORONARY ARTERY DISEASES IN CAN THO

Tran Anh Thu Truong1,, Gia Han Diep1, Thi Kim Huyen Vuong1, Van Thanh Le 1, Van Quyen Vo 1, Anh Nhut Nguyen 2, Thi Cam Tu Le 1, Thang Nguyen 1
1 Can Tho University of Medicine and Pharmacy
2 Ho Chi Minh University of Medicine and Pharmacy

Main Article Content

Abstract

 Background: Drug–drug interactions could cause failure in treatment and adverse events. Objectives: To determine the prevalence and characteristics of drug-drug interactions in treatment for coronary artery diseases. Materials and methods: We conducted a cross-sectional study on the prescribing for outpatients with coronary artery diseases at a hospital in Can Tho in August 2018. The drugs were recorded from the prescriptions and the drug-drug interactions were checked on Drugs.com website. We used only major drug-drug interactions. Results: In total, 683 patient’s prescription were included (mean age 63.4; 64.3% female). The prevalence of drug- drug interactions is 19.3%. The interaction between clopidogrel and proton pump inhibitors-PPIs (omeprazole, esomeprazole, rabeprazole) is the most common in the study. Patients who received five or more drugs were more likely to experience drug-drug interactions (OR = 6.36; 95% CI: 2.54-15.96). Conclusion: Drug-drug interactions are common among patients with coronary artery diseases. The incidence of drug-drug interactions increased with the increase in number of drugs prescribed. Further studies should be conducted to determine the association between drug-drug interactions and physicians’ characteristics.

Article Details

Keywords

Drug-related problems, Drug-drug interactions, Coronary artery diseases, Can Tho

References

1. Benjamin E. J, Muntner P, Alonso A, et al (2019), Heart Disease and Stroke Statistics-2019 Ata-Glance Heart Disease, Stroke and other Cardiovascular Diseases, Am Hear Assoc, 1–5.
2. World Health Organization (2018), Noncommunicable Diseases Country Profiles 2018, WHO, 369, 1336–43.
3. Palleria C, Di Paolo A, Giofrè C, et al. (2013), Pharmacokinetic drug-drug interaction and their implication in clinical management, J Res Med Sci, 18(7), 601–610.
4. Makiani M. J, Nasiripour S, Hosseini M, Mahbubi A (2017), Drug-drug Interactions: The Importance of Medication Reconciliation, J Res Pharm Pract, 6(1), 61–62.
5. Murtaza G, Khan M. Y, Azhar S, Khan S. A, Khan T. M (2016), Assessment of potential drug-drug interactions and its associated factors in the hospitalized cardiac patients, Saudi Pharm J, 24(2), 220–225.
6. Kulkarni V, Bora S. S, Sirisha S, Saji M, Sundaran S (2013), A study on drug-drug interactions through prescription analysis in a South Indian teaching hospital, Ther Adv Drug Saf, 4(4), 141-6.
7. Shetty V, Chowta M. N, Chowta K. N, Shenoy A, Kamath A,Kamath P (2018), Evaluation of Potential Drug-Drug Interactions with Medications Prescribed to Geriatric Patients in a Tertiary Care Hospital, J Aging Res, 2018, 5728957.
8. Serbin M. A, Guzauskas G. F,Veenstra D. L (2016), Clopidogrel-Proton Pump Inhibitor Drug-Drug Interaction and Risk of Adverse Clinical Outcomes Among PCI-Treated ACS Patients: A Meta-analysis, J Manag Care Spec Pharm, 22(8), 939-47.
9. Serbin M. A, Guzauskas G. F, Veenstra D. L (2016), Clopidogrel-Proton Pump Inhibitor Drug-Drug Interaction and Risk of Adverse Clinical Outcomes Among PCI-Treated ACS Patients: A Meta-analysis, J Manag Care Spec Pharm, 22(8), 939–947.
10. Bundhun P. K, Teeluck A. R, Bhurtu A, Huang W. Q (2017), Is the concomitant use of clopidogrel and Proton Pump Inhibitors still associated with increased adverse cardiovascular outcomes following coronary angioplasty?: a systematic review and metaanalysis of recently published studies (2012 - 2016), BMC Cardiovascular Disor, 17(1), 3.
11. Wu J, Jia L. T, Shao L. M, et al. (2013), Drug-drug interaction of rabeprazole and clopidogrel in healthy Chinese volunteers, Eur J Clin Pharmacol, 69(2):179 187.
12. Funck-Brentano C, Szymezak J, Steichen O, et al. (2013), Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers, Arch Cardiovasc Dis, 106(12):661 671.
13. Guérin A, Mody R, Carter V, Ayas C, Patel, H, Lasch K, Wu E (2016), Changes in Practice Patterns of Clopidogrel in Combination with Proton Pump Inhibitors after an FDA Safety Communication, PloS one, 11(1), e0145504.
14. Farhat N, Haddad N, Crispo J, Birkett N, McNair D, Momoli F, Wen S. W, Mattison D. R, Krewski D (2019), Trends in concomitant clopidogrel and proton pump inhibitor treatment among ACS inpatients, 2000-2016, Eur J Clin Pharmacol, 75(2), 227-235.
15. Chatsisvili A, Sapounidis I, Pavlidou G, et al. (2010), Potential drug-drug interactions in prescriptions dispensed in community pharmacies in Greece, Pharm World Sci, 32, 187–193